2 results
Approved WMOCompleted
The objective of the present study is to characterize the dose-response relationship of PURETHAL® Mites (PM) with a nasal provocation test in order to identify the optimal dose in terms of highest clinical efficacy and safety.
DDAVP treatment combined with FVIII clotting factor concentrates in patients with mild hemophilia A.
Primary objectives:To assess the proportion of non-severe hemophilia A patients within FVIII target levels with the DDAVP and FVIII concentrate combination treatment in the first 72 hours after the start of combination treatment, without adding off-…